Fighting the Uphill Battle: Current Evidence in Obesity Management

Format: Webcourse
Credit(s): 1.00 (60 min)
Release Date: Mar 15, 2019
Expiration Date: Mar 15, 2020
Credit Type(s):
  • CME / AMA PRA Category 1 Credit™

PROGRAM OVERVIEW

The current obesity epidemic shows no signs of slowing down and the factors driving it are numerous, including patient and clinician attitudes toward weight loss, a lack of clinician familiarity with guidelines, a lack of effective long-term weight-loss options, and a hesitancy among physicians to recognize obesity as a medical condition and discuss weight with their patients. Recent evidence demonstrates that primary care providers are hesitant to recommend weight-loss pharmacotherapies even in guideline-recommended settings, and many clinicians who do recommend pharmacotherapies prescribe them for too short of a course.

“Fighting the Uphill Battle: Current Evidence in Obesity Management” will provide clinicians with the latest evidence regarding obesity management in a form that can be readily integrated into practice. Clinicians will also receive real-world strategies for effectively addressing weight with their patients and initiating conversations that can begin to reverse the obesity trend that pervades society.

This course is also now available on your Alexa enabled device!  Click here for more information.

AGENDA

Current Scope and Impact of Obesity on Population Health
How to Discuss Obesity with Your Patients
Evaluate the Roles and Risks/Benefits of Behavioral and Pharmacological Weight-loss Interventions

TARGET AUDIENCE

This activity is intended for primary care providers including family medicine, internal medicine, and other primary care clinicians who care for patients with obesity.

EDUCATIONAL OBJECTIVES

At the conclusion of this activity, participants should be able to demonstrate the ability to:

  • Adopt strategies to foster effective discussions about weight loss with patients who are overweight
  • Evaluate the roles and risks/benefits of behavioral and pharmacological weight-loss interventions
  • Integrate guideline recommendations for assessing obesity in patients and making evidence-based recommendations for weight loss

ACCREDITATION

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Boston University School of Medicine and Rockpointe. Boston University School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

CREDIT DESIGNATION

Boston University School of Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

For information about the accreditation of this program, please email: cme@bu.edu.

AMERICAN ACADEMY OF FAMILY PHYSICIANS (AAFP) CREDIT

This Enduring Material activity, Fighting the Uphill Battle: Current Evidence in Obesity Management, has been reviewed and is acceptable for up to 1.00 Prescribed credit(s) by the American Academy of Family Physicians. AAFP certification begins 3/15/2019. Term of approval is for one year from this date. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

FACULTY

Harold Bays, MD, FOMA, FTOS, FACC, FACE, FNLA​
Medical Director / President
Louisville Metabolic and Atherosclerosis Research Center
Your Body Goal
Louisville, KY
Harold Bays, MD, FOMA, FTOS, FACC, FACE, FNLA​ is the Medical Director of the Louisville Metabolic and Atherosclerosis Research Center, Inc. (L-MARC). He has served as a Principal Investigator for more than 500 clinical trials, including research into anti-obesity therapeutic agents. Dr. Bays is board-certified in internal medicine and endocrinology and metabolism and serves as a Diplomate of the American Board of Obesity Medicine and the American Board of Clinical Lipidology. He is a Fellow of the Obesity Medicine Association (OMA), Obesity Society, American College of Cardiology, American Association of Clinical Endocrinologists, and National Lipid Association (NLA).

Dr. Bays has written or served as a contributing author to more than 200 scientific manuscripts and book chapters, and authored/presented hundreds of scientific abstracts. He has served as a Board Director and Executive Officer of scientific organizations, served as the Chairman for many scientific projects, and authored a number of scientific consensus statements and national recommendations. He is a member of the Board of Trustees of the OMA and, since 2013, has served as the Medical Writer for the OMA Obesity Algorithm. Among his awards are the 2015 NLA “President’s Service Award” and the 2016 OMA “Obesity Medicine Clinician of the Year.”
Donna Ryan, MD, FTOS
Professor Emerita
Pennington Biomedical Research Center
New Orleans, LA
Donna Ryan, MD, FTOS is Professor Emerita at Pennington Biomedical in Baton Rouge, LA, and current President of the World Obesity Federation. She is Associate Editor-in-Chief of the journal Obesity and has authored more than 200 publications, primarily on obesity. Dr. Ryan’s research focuses on nutrition, obesity, and obesity comorbidities. She has been an investigator for various US National Institutes of Health-sponsored studies, including Pounds Lost, DASH (Dietary Approaches to Stop Hypertension), DPP (Diabetes Prevention Program), and the Look AHEAD study.

Dr. Ryan’s continuing interests focus on translation of effective weight management into primary care practices. She served as Co-chair on the expert panel for the 2013 American College of Cardiology (ACC), American Heart Association (AHA), and The Obesity Society (TOS) evidence-based Guidelines on the Evaluation and Management of Overweight and Obesity in Adults. She was a panel member of the 2015 Endocrine Society Systematic Evidence Review and Guidelines for Medications that Affect Body Weight and is Co-chair of the Steering Committee SELECT, a cardiovascular outcome trial of semaglutide.

DISCLOSURES OF CONFLICTS OF INTEREST

This educational activity has been produced in adherence with the policies and guidelines, including the Standards for Commercial Support, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous.

Boston University School of Medicine asks all individuals, and their spouses/partners, involved in the development and presentation of Continuing Medical Education (CME) and Continuing Nursing Education (CNE) activities to disclose all relevant financial relationships with commercial interests. This information is disclosed to CME activity participants prior to the start of the educational activity. Boston University School of Medicine has procedures to resolve all conflicts of interest. In addition, faculty members are asked to disclose when any unapproved use of pharmaceuticals and devices is being discussed.

Program Faculty Disclosures

The program faculty reported the following relevant financial relationships that they or their spouse/partner have with commercial interests:

Harold Bays, MD, FOMA, FTOS, FACC, FACE, FNLA: Consultant: Amgen; Research/Grant Support: Amgen, Eisai, Johnson & Johnson, Novo Nordisk

Donna Ryan, MD, FTOS: Consultant: Amgen, Celtic, Epitomee, Gila Therapeutics, Janssen, KVK Tech, Novo Nordisk, Phenomix, Real Appeal, Sanofi, Scientific Intake; Speaker: Novo Nordisk; Stock Ownership: Epitomee, Gila Therapeutics, Phenomix, Scientific Intake

Non-faculty Content Contributors Disclosures

Non-faculty content contributors and/or reviewers reported the following relevant financial relationships that they or their spouse/partner have with commercial interests:

Caroline Apovian, MD: Consultant: EnteroMedics, Ferring, Gelesis, Merck, Novo Nordisk, Nutrisystem, Orexigen, Sanofi-Aventis, Scientific Intake, Takeda, Zafgen; Grant/Research Support: Aspire Bariatrics, Gelesis, GI Dynamics, MetaProteomics, MYOS Corporation, Orexigen, Pfizer, Takeda, The Dr. Robert C. and Veronica Atkins Foundation; Stockholder: Science Smart LLC

Chad Williamson, MS, MBA, CMPP; Blair St. Amand; Natalie Sanfratello; Elizabeth Drury; Brian Jack, MD (AAFP Reviewer): Nothing to disclose

DISCLAIMER

THIS CONTINUING MEDICAL EDUCATION PROGRAM IS INTENDED SOLELY FOR EDUCATIONAL PURPOSES FOR QUALIFIED HEALTH CARE PROFESSIONALS. IN NO EVENT SHALL BOSTON UNIVERSITY BE LIABLE FOR ANY DECISION MADE OR ACTION TAKEN IN RELIANCE ON THE INFORMATION CONTAINED IN THE PROGRAM. IN NO EVENT SHOULD THE INFORMATION CONTAINED IN THE PROGRAM BE USED AS A SUBSTITUTE FOR PROFESSIONAL CARE. NO PHYSICIAN-PATIENT RELATIONSHIP IS BEING ESTABLISHED.

FDA DISCLOSURE

The contents of some CME/CE activities may contain discussions of non-approved or off-label uses of some agents mentioned. Please consult the prescribing information for full disclosure of approved uses.

SYSTEM REQUIREMENTS

In order to view this presentation, your computer must have audio capabilities (working speakers or headphones) and must have an internet browser capable of playing an HTML5 video.

INSTRUCTIONS FOR PARTICIPANTS AND OBTAINING CME CREDIT

There is no fee for this activity. To receive credit, participants must take the pre-test, view this CME activity in its entirety, and then complete the post-test, with a score of 70% or better, and evaluation. The estimated time for completion of this activity is 1 hour. To receive their certificates, participants must demonstrate mastery of the presented material via the post-test. Participant is allowed to take the post-test multiple times.

COURSE TRANSCRIPT

Slide 1 – Title Slide Harold Edward Bays, MD: Hello and welcome to the CME-certified program, “Fighting the Uphill Battle: Current Evidence in Obesity Management.” This program is supported by an educational grant from Novo Nordisk and is provided by Boston University School of Medicine and Rockpointe. Slide 2 – Program Faculty My name is Harold Edward Bays, MD and I’m a Medical Director and President of the Louisville Metabolic and Atherosclerosis Research Center located in Louisville, Kentucky. It is with great pleasure that I’ve had the opportunity to help develop the content of this program with my colleague and co-presenter, Donna H. Ryan, MD, who is professor emerita of the Pennington Biomedical Research Center in New Orleans, Louisiana. Slide 3 – Disclosures On the next slide, you can see the disclosures. Slide 4 – Educational Objectives The educational objectives of this program are to help ensure that at the conclusion of this activity you’re going to be able to adopt strategies to foster effective discussion about weight loss in patients who are overweight. We’re going to evaluate the roles and risks and benefits of behavioral interventions and pharmacological weight loss interventions and finally, we’re going to see how to integrate guideline recommendations for assessing obesity in patients and making evidence-based recommendations for weight loss. For a full transcript, click here.

PROVIDER

Jointly provided by Boston University School of Medicine and Rockpointe

     Rockpointe

SUPPORTER

This activity is supported by an educational grant from Novo Nordisk Inc.

RELATED COURSES

Updates for Migraine Management in Primary Care

Learn More

Updates for Migraine Management in Primary Care

Credits 1.00 (60 min)

Format Webcourse

Improving Outcomes for Patients with Severe Hypercholesterolemia

Learn More

Role of Interventional Cardiologists in Secondary Prevention of Acute Coronary Syndromes: Redefining Clinical Practice

Learn More
This entry was posted in . Bookmark the permalink.

Follow Us :

Follow Us :

© 2021 Rockpointe Corporation

Privacy Policy

© 2021 Rockpointe Corporation

Privacy Policy